At first, the path to market appeared relatively direct. The underlying science had a credible basis. The screening process was fast and easy to administer. The potential need was significant. It was tempting to think that the principal challenge would be introducing the technology to the right buyers.
The engagement taught us otherwise.
The real work was not explaining why the technology was interesting. It was determining exactly what the evidence would allow anyone to say about it.
That began with intended use. What is the screening instrument designed to identify? What does a positive result mean? Equally important, what does it not mean? Who should be screened, under what circumstances, and what independent clinical evaluation should follow?
Until those questions are answered precisely, validation cannot be designed properly and commercialization cannot be planned responsibly.
A study must be capable of finding failure
As we worked through the requirements for clinical evaluation, one question sharpened our thinking: Would the study be capable of identifying the people the screening instrument failed to flag?
If only people with positive screening results receive an appropriate independent clinical assessment, the study may confirm some positive findings—but it cannot reliably determine how often the instrument misses people it should have identified. Without evaluating an appropriate group of screen-negative participants, false negatives remain largely invisible.
That limitation matters. Sensitivity and specificity are not persuasive labels that can be added after a study. They depend on a design capable of identifying both correct and incorrect results across positive and negative populations.
A study can therefore generate encouraging findings and still fail to answer the question the market will eventually ask: How reliably does this work in the population and setting for which it is intended?
Validation must be designed around the proposed use and claims—not merely around the results that are easiest to collect.
Scientific credibility is only the beginning
The engagement also taught us to distinguish more carefully among several ideas that are often treated as interchangeable.
A credible scientific relationship does not establish that a particular product accurately detects a condition. An accurate screening result does not necessarily establish clinical utility. Clinical utility does not by itself establish that the product fits existing workflows. And none of those conclusions automatically determines how the product may be described, regulated, reimbursed, or marketed.
Each step requires its own evidence and decisions.
This does not diminish the underlying science. It places the science into a structure through which others can evaluate, trust, and use it responsibly.
Commercialization cannot be designed separately
The engagement reinforced that clinical, regulatory, operational, and commercial planning are not separate workstreams that can be completed independently.
The intended use shapes the study. The study shapes the evidence. The evidence defines the claims. The claims affect the regulatory pathway. The regulatory position and clinical workflow influence who can use the product, who may buy it, what training and follow-up are required, and whether distribution can be scaled responsibly.
A weakness anywhere in that chain eventually becomes a commercial weakness.
The appropriate response is not to stop planning for the market while validation proceeds. It is to design the market pathway around explicit evidence gates. Commercial preparation can continue, but claims, commitments, and distribution should not move ahead of what has been established.
What discipline looks like
Our work with this company has helped sharpen our own definition of responsible healthcare commercialization.
It means being willing to separate what is scientifically plausible from what has been clinically demonstrated. It means examining whether a proposed study can identify failure as rigorously as it can document success. It means treating intended use, regulatory requirements, workflow, and distribution as parts of one system. And it means accepting that a promising technology may need additional work before the market should be asked to trust it.
That is not a delay imposed upon innovation. It is the work required to translate innovation into something credible, usable, and durable.
The engagement began with a technology that appeared ready to be introduced.
It taught us that the more important question was whether it was ready to be trusted.